Key result
ApoC3 inhibitors substantially reduce triglycerides and acute pancreatitis risk in familial chylomicronemia syndrome.
Why the study?
In familial chylomicronaemia syndrome (FCS), chylomicronaemia and the risk of acute pancreatitis persist even with excellent adherence to a fat-restricted diet, motivating an evaluation of emerging apoC3-directed precision therapies.
Do apoC3-directed precision therapies and emerging molecular approaches reduce triglycerides, chylomicronemia, and acute pancreatitis risk in patients with familial chylomicronemia syndrome?
Do apoC3-directed precision therapies and emerging molecular approaches reduce triglycerides, chylomicronemia, and acute pancreatitis risk in patients with familial chylomicronemia syndrome?
Answers are grounded in this paper and cite their sources.
ApoC3-targeted therapies (volanesorsen, olezarsen, and plozasiran) represent a major breakthrough in managing familial chylomicronemia syndrome by offering durable triglyceride and pancreatitis risk reductions beyond an ultra-low-fat diet.
Background and Objective: Familial chylomicronaemia syndrome (FCS) is a rare disease characterised by persistent fasting chylomicronaemia and severe hypertriglyceridaemia, predisposing individuals to recurrent episodes of acute pancreatitis. Treatment strategies focus on a fat-restricted diet to lower triglycerides and reduce the risk of pancreatitis. However, even with excellent dietary adherence, chylomicronaemia and risk of pancreatitis persists. This review outlines the biological basis of FCS and evaluates emerging therapeutic strategies, with emphasis on apolipoprotein C3 (apoC3) directed precision treatment.Methods: A literature search was conducted using PubMed/MEDLINE and Google Scholar from date of inception to June 2026. Titles and abstracts were screened for relevance, and the reference lists of included articles were also reviewed to identify additional relevant studies. Non-English language publications were excluded.Key Content and Findings: Maintaining an ultra-low-fat diet remains the cornerstone of management in FCS and there is only a limited role for traditional lipid-lowering therapies. ApoC3 inhibition with the antisense oligonucleotide (ASO), volanesorsen, demonstrates substantial chylomicronaemia reduction and importantly, reduced pancreatitis risk. Next generation GalNAc₃-conjugated therapies (olezarsen and plozasiran) targeting apoC3 provide comparable efficacy to volanesorsen with improved safety and tolerability. Therapies targeting angiopoietin-like proteins (ANGPTLs) and microsomal triglyceride transfer protein (MTTP) show emerging potential for triglyceride and chylomicronaemia reduction. Advances in gene-editing technology shows promise as a future treatment strategy.Conclusions: Recent advances in technologies targeting apoC3 inhibition represent a significant breakthrough in the management of FCS providing effective and durable reductions in triglycerides and pancreatitis risk. Emerging molecular and gene-editing approaches hold promise for further advances in precision treatment.
No takes yet. Share an insight, caveat, or question.
Maarouf et al. (2026) conducted a review in Familial chylomicronemia syndrome (FCS) with persistent fasting chylomicronemia and severe hypertriglyceridemia. ApoC3-directed precision therapies (volanesorsen, olezarsen, plozasiran) and emerging ANGPTL, MTTP, and gene-editing strategies vs. Ultra-low-fat diet and traditional lipid-lowering therapies was evaluated on Triglyceride/chylomicronemia reduction and acute pancreatitis risk reduction. ApoC3-targeting therapies (volanesorsen, olezarsen, plozasiran) substantially reduce chylomicronemia, triglycerides, and acute pancreatitis risk in familial chylomicronemia syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: